Published • loading... • Updated
Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy - BioTuesdays
Valion Bio (NASDAQ: VBIO) has announced a major clinical development milestone with the finalization of a clinical trial protocol at Sheba Medical Center, one of the world’s leading hospitals, to evaluate Entolimod in cancer patients receiving high doses of irradiation for a rare form of cancer. Under the collaboration, Sheba will self-fund and conduct the clinical trial, while Valion will provide the investigational drug. According to Valion’s …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
